Key points are not available for this paper at this time.
Methylphenidate (MPH) is a common treatment of attention-deficit/hyperactivity disorder (ADHD). Concern has been raised regarding its cardiovascular safety, partly in relation with its micromolar affinity for the 5-HT
Ayme‐Dietrich et al. (Sat,) studied this question.